Caffeine
CAFCIT
What it isAdenosine receptor antagonist; alertness, analgesic adjunct, and apnea of prematurity.
Why this oneIn neonates it reduces apnea and improves neurodevelopmental outcome, which is a genuine therapeutic use rather than a stimulant one.
What limits itTolerance and withdrawal headache. A CYP1A2 substrate, so fluvoxamine and ciprofloxacin raise levels sharply, and smoking lowers them.
FDA-approved for
- apnea of prematurity (~1999)
Off-label
- post-dural-puncture headache
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Not stated in fetched sections (OTC alertness aid — Uses/Purpose section absent) | Adults & children ≥12 yr | 1 tablet q3–4h PRN | 1 tablet q3–4h PRN | 1 tablet q3h (no daily cap stated) |
Renal Undefined
Hepatic Undefined
Do not take more often than every 3 to 4 hours.
Instructions
- Children <12 yr: do not use.
Pregnancy Undefined
Lactation Undefined
NO BOXED WARNINGS
Principal riskWithdrawal headache; CYP1A2 interactions
Classes and tags
Clinical profile
Mechanism of action: Caffeine ballicule
Open Caffeine in the interactive console ↗
Memory aids: mascots and interaction avatars
